Waseem Qasim

List of Publications by Citations

116 papers	4,974 citations	38 h-index	67 g-index
126 ext. papers	6,083 ext. citations	6.4 avg, IF	5.22 L-index

#	Paper	IF	Citations
116	Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. *Science Translational Medicine*, **2017**, 9,	17.5	524
115	Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative study. *Blood*, **2011**, 118, 1675-84	2.2	236
114	Comprehensive Rare Variant Analysis via Whole-Genome Sequencing to Determine the Molecular Pathology of Inherited Retinal Disease. *American Journal of Human Genetics*, **2017**, 100, 75-90	11	235
113	Human Coronavirus OC43 Associated with Fatal Encephalitis. *New England Journal of Medicine*, **2016**, 375, 497-8	59.2	176
112	Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells. *Blood*, **2005**, 106, 3062-7	2.2	161
111	Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: An international multicenter retrospective study. *Journal of Allergy and Clinical Immunology*, **2018**, 141, 1036-1049.e5	11.5	157
110	Astrovirus VA1/HMO-C: an increasingly recognized neurotropic pathogen in immunocompromised patients. *Clinical Infectious Diseases*, **2015**, 60, 881-8	11.6	139
109	Treosulfan-based conditioning regimens for hematopoietic stem cell transplantation in children with primary immunodeficiency: United Kingdom experience. *Blood*, **2011**, 117, 4367-75	2.2	124
108	Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient. *Journal of Hepatology*, **2015**, 62, 486-91	13.4	123
107	Clinical and immunological manifestations of patients with atypical severe combined immunodeficiency. *Clinical Immunology*, **2011**, 141, 73-82	9	122
106	Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS prodigy. *Cytotherapy*, **2016**, 18, 1002-1011	4.8	114
105	Loss-of-function nuclear factor B subunit 1 (NFKB1) variants are the most common monogenic cause of common variable immunodeficiency in Europeans. *Journal of Allergy and Clinical Immunology*, **2018**, 142, 1285-1296	11.5	109
104	Impact of viral reactivations in the era of pre-emptive antiviral drug therapy following allogeneic haematopoietic SCT in paediatric recipients. *Bone Marrow Transplantation*, **2013**, 48, 803-8	4.4	99
103	Allogeneic hematopoietic stem-cell transplantation for leukocyte adhesion deficiency. *Pediatrics*, **2009**, 123, 836-40	7.4	99
102	Omission of in vivo T-cell depletion promotes rapid expansion of naïve CD4+ cord blood lymphocytes and restores adaptive immunity within 2 months after unrelated cord blood transplant. *British Journal of Haematology*, **2012**, 156, 656-66	4.5	94
101	T-cell receptor and CD19 cell-depleted haploidentical and mismatched hematopoietic stem cell transplantation in primary immune deficiency. *Journal of Allergy and Clinical Immunology*, **2018**, 141, 1417-1426.e1	11.5	85
100	FOXRED1, encoding an FAD-dependent oxidoreductase complex-I-specific molecular chaperone, is mutated in infantile-onset mitochondrial encephalopathy. *Human Molecular Genetics*, **2010**, 19, 4837-47	5.6	73

99	Inherited GINS1 deficiency underlies growth retardation along with neutropenia and NK cell deficiency. *Journal of Clinical Investigation*, **2017**, 127, 1991-2006	15.9	73
98	Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. *Lancet, The*, **2020**, 396, 1885-1894	40	71
97	Long Terminal Repeat CRISPR-CAR-Coupled "Universal" T Cells Mediate Potent Anti-leukemic Effects. *Molecular Therapy*, **2018**, 26, 1215-1227	11.7	68
96	How I treat severe combined immunodeficiency. *Blood*, **2013**, 122, 3749-58	2.2	67
95	Identifying functional defects in patients with immune dysregulation due to LRBA and CTLA-4 mutations. *Blood*, **2017**, 129, 1458-1468	2.2	64
94	Hematopoietic stem cell transplantation in 29 patients hemizygous for hypomorphic /NEMO mutations. *Blood*, **2017**, 130, 1456-1467	2.2	61
93	Autologous transplantation of amniotic fluid-derived mesenchymal stem cells into sheep fetuses. *Cell Transplantation*, **2011**, 20, 1015-31	4	61
92	First Clinical Application of Talen Engineered Universal CAR19 T Cells in B-ALL. *Blood*, **2015**, 126, 2046-2046	2.2	61
91	Signal transducer and activator of transcription 2 deficiency is a novel disorder of mitochondrial fission. *Brain*, **2015**, 138, 2834-46	11.2	59
90	Sleeping beauty transposition from nonintegrating lentivirus. *Molecular Therapy*, **2009**, 17, 1197-204	11.7	59
89	Progress and prospects: gene therapy for inherited immunodeficiencies. *Gene Therapy*, **2009**, 16, 1285-91	4	59
88	Cord blood T cells mediate enhanced antitumor effects compared with adult peripheral blood T cells. *Blood*, **2015**, 126, 2882-91	2.2	52
87	Ex-vivo gene therapy restores LEKTI activity and corrects the architecture of Netherton syndrome-derived skin grafts. *Molecular Therapy*, **2011**, 19, 408-16	11.7	52
86	Preliminary Data on Safety, Cellular Kinetics and Anti-Leukemic Activity of UCART19, an Allogeneic Anti-CD19 CAR T-Cell Product, in a Pool of Adult and Pediatric Patients with High-Risk CD19+ Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia. *Blood*, **2018**, 132, 896-896	2.2	52
85	Treosulfan and Fludarabine Conditioning for Hematopoietic Stem Cell Transplantation in Children with Primary Immunodeficiency: UK Experience. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 529-536	4.7	51
84	Immune reconstitution and recovery of FOXP3 (forkhead box P3)-expressing T cells after transplantation for IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked) syndrome. *Pediatrics*, **2008**, 121, e998-1002	7.4	46
83	Third-party virus-specific T cells eradicate adenoviraemia but trigger bystander graft-versus-host disease. *British Journal of Haematology*, **2011**, 154, 150-3	4.5	45
82	Clinical and immunologic outcome of patients with cartilage hair hypoplasia after hematopoietic stem cell transplantation. *Blood*, **2010**, 116, 27-35	2.2	45

81	Novel lentiviral vectors with mutated reverse transcriptase for mRNA delivery of TALE nucleases. *Scientific Reports*, **2014**, 4, 6409	4.9	42
80	TCR/CD3 disruption enables CD3-specific antileukemic T cell immunotherapy. *JCI Insight*, **2018**, 3,	9.9	41
79	Host natural killer immunity is a key indicator of permissiveness for donor cell engraftment in patients with severe combined immunodeficiency. *Journal of Allergy and Clinical Immunology*, **2014**, 133, 1660-6	11.5	38
78	Allogeneic CAR T cell therapies for leukemia. *American Journal of Hematology*, **2019**, 94, S50-S54	7.1	35
77	Lentiviral Engineered Fibroblasts Expressing Codon-Optimized COL7A1 Restore Anchoring Fibrils in RDEB. *Journal of Investigative Dermatology*, **2016**, 136, 284-92	4.3	34
76	Capture and generation of adenovirus specific T cells for adoptive immunotherapy. *British Journal of Haematology*, **2007**, 136, 117-26	4.5	34
75	Lentiviral vectors for T-cell suicide gene therapy: preservation of T-cell effector function after cytokine-mediated transduction. *Molecular Therapy*, **2007**, 15, 355-60	11.7	34
74	Comparison of lentiviral and sleeping beauty mediated T cell receptor gene transfer. *PLoS ONE*, **2013**, 8, e68201	3.7	33
73	Phase I study protocol for ex vivo lentiviral gene therapy for the inherited skin disease, Netherton syndrome. *Human Gene Therapy Clinical Development*, **2013**, 24, 182-90	3.2	30
72	Safety and early efficacy outcomes for lentiviral fibroblast gene therapy in recessive dystrophic epidermolysis bullosa. *JCI Insight*, **2019**, 4,	9.9	30
71	Characterization of the clinical and immunologic phenotype and management of 157 individuals with 56 distinct heterozygous NFKB1 mutations. *Journal of Allergy and Clinical Immunology*, **2020**, 146, 901-911	11.5	29
70	Deep sequencing reveals persistence of cell-associated mumps vaccine virus in chronic encephalitis. *Acta Neuropathologica*, **2017**, 133, 139-147	14.3	29
69	One hundred percent survival after transplantation of 34 patients with Wiskott-Aldrich syndrome over 20 years. *Journal of Allergy and Clinical Immunology*, **2018**, 142, 1654-1656.e7	11.5	29
68	Interferon- capture T cell therapy for persistent Adenoviraemia following allogeneic haematopoietic stem cell transplantation. *British Journal of Haematology*, **2013**, 161, 449-52	4.5	28
67	Comprehensive Cancer-Predisposition Gene Testing in an Adult Multiple Primary Tumor Series Shows a Broad Range of Deleterious Variants and Atypical Tumor Phenotypes. *American Journal of Human Genetics*, **2018**, 103, 3-18	11	27
66	T cell receptor-therapy in HBV-related hepatocellularcarcinoma. *OncoImmunology*, **2015**, 4, e1008354	7.2	27
65	T cell transduction and suicide with an enhanced mutant thymidine kinase. *Gene Therapy*, **2002**, 9, 824-7	4	26
64	New graft manipulation strategies improve the outcome of mismatched stem cell transplantation in children with primary immunodeficiencies. *Journal of Allergy and Clinical Immunology*, **2019**, 144, 280-293	11.5	25

63	Frequent occurrence of cytomegalovirus retinitis during immune reconstitution warrants regular ophthalmic screening in high-risk pediatric allogeneic hematopoietic stem cell transplant recipients. *Clinical Infectious Diseases*, **2014**, 58, 1700-6	11.6	25
62	Gene therapy strategies to exploit TRIM derived restriction factors against HIV-1. *Viruses*, **2014**, 6, 243-63	3.2	25
61	Impaired EIF2S3 function associated with a novel phenotype of X-linked hypopituitarism with glucose dysregulation. *EBioMedicine*, **2019**, 42, 470-480	8.8	24
60	Gene therapy for primary immunodeficiencies: current status and future prospects. *Drugs*, **2014**, 74, 963-9	12.1	24
59	Mutations in linker for activation of T□cells (LAT) lead to a novel form of severe combined immunodeficiency. *Journal of Allergy and Clinical Immunology*, **2017**, 139, 634-642.e5	11.5	24
58	Management of adenovirus in children after allogeneic hematopoietic stem cell transplantation. *Advances in Hematology*, **2013**, 2013, 176418	1.5	24
57	Effect of stem cell source on long-term chimerism and event-free survival in children with primary immunodeficiency disorders after fludarabine and melphalan conditioning regimen. *Journal of Allergy and Clinical Immunology*, **2016**, 138, 1152-1160	11.5	22
56	Production and first-in-man use of T cells engineered to express a HSVTK-CD34 sort-suicide gene. *PLoS ONE*, **2013**, 8, e77106	3.7	21
55	Cell-specific and efficient expression in mouse and human B cells by a novel hybrid immunoglobulin promoter in a lentiviral vector. *Gene Therapy*, **2007**, 14, 1623-31	4	19
54	Gene therapy for severe combined immune deficiency. *Expert Reviews in Molecular Medicine*, **2004**, 6, 1-15	6.7	19
53	Variability in Genome Editing Outcomes: Challenges for Research Reproducibility and Clinical Safety. *Molecular Therapy*, **2020**, 28, 1422-1431	11.7	18
52	De Novo Truncating Mutations in WASF1 Cause Intellectual Disability with Seizures. *American Journal of Human Genetics*, **2018**, 103, 144-153	11	18
51	Bi-allelic Loss-of-Function CACNA1B Mutations in Progressive Epilepsy-Dyskinesia. *American Journal of Human Genetics*, **2019**, 104, 948-956	11	17
50	Cord blood transplantation recapitulates fetal ontogeny with a distinct molecular signature that supports CD4 T-cell reconstitution. *Blood Advances*, **2017**, 1, 2206-2216	7.8	17
49	Alternative donor SCT for the treatment of MHC class II deficiency. *Bone Marrow Transplantation*, **2013**, 48, 226-32	4.4	17
48	Lentiviral gene therapy against human immunodeficiency virus type 1, using a novel human TRIM21-cyclophilin A restriction factor. *Human Gene Therapy*, **2012**, 23, 1176-85	4.8	17
47	Immune reconstitution following hematopoietic stem cell transplantation using different stem cell sources. *Expert Review of Clinical Immunology*, **2019**, 15, 735-751	5.1	16
46	Variable phenotype of severe immunodeficiencies associated with RMRP gene mutations. *Journal of Clinical Immunology*, **2015**, 35, 147-57	5.7	15

45	Generation and Clinical Application of Gene-Modified Autologous Epidermal Sheets in Netherton Syndrome: Lessons Learned from a Phase 1 Trial. *Human Gene Therapy*, **2019**, 30, 1067-1078	4.8	15
44	Anticardiolipin antibodies and thromboembolism after BMT. *Bone Marrow Transplantation*, **1998**, 21, 845-7	4.4	15
43	Gene therapies for inherited skin disorders. *Seminars in Cutaneous Medicine and Surgery*, **2014**, 33, 83-90	1.4	15
42	Biallelic Mutation of ARHGEF18, Involved in the Determination of Epithelial Apicobasal Polarity, Causes Adult-Onset Retinal Degeneration. *American Journal of Human Genetics*, **2017**, 100, 334-342	11	14
41	Progress and prospects for engineered T cell therapies. *British Journal of Haematology*, **2014**, 166, 818-29	4.5	13
40	CD70 expression determines the therapeutic efficacy of expanded human regulatory T cells. *Communications Biology*, **2020**, 3, 375	6.7	13
39	Base-edited CAR T cells for combinational therapy against T cell malignancies. *Leukemia*, **2021**, 35, 3466-3481	14.1	13
38	Protein assays for diagnosis of Wiskott-Aldrich syndrome and X-linked thrombocytopenia. *British Journal of Haematology*, **2001**, 113, 861-5	4.5	12
37	Adoptive T-cell therapy for cancer in the United kingdom: a review of activity for the British Society of Gene and Cell Therapy annual meeting 2015. *Human Gene Therapy*, **2015**, 26, 276-85	4.8	11
36	Hybrid lentiviral vectors. *Molecular Therapy*, **2010**, 18, 1263-7	11.7	11
35	Manufacture of GMP-compliant functional adenovirus-specific T-cell therapy for treatment of post-transplant infectious complications. *Cytotherapy*, **2016**, 18, 1209-18	4.8	11
34	Umbilical cord blood transplantation without in vivo T-cell depletion for children with MHC class II deficiency. *Journal of Allergy and Clinical Immunology*, **2018**, 141, 2279-2282.e2	11.5	11
33	Hematopoietic stem cell transplantation for cytidine triphosphate synthase 1 (CTPS1) deficiency. *Bone Marrow Transplantation*, **2019**, 54, 130-133	4.4	10
32	Update on clinical gene therapy in childhood. *Archives of Disease in Childhood*, **2007**, 92, 1028-31	2.2	10
31	Lentiviral Vector Production Titer Is Not Limited in HEK293T by Induced Intracellular Innate Immunity. *Molecular Therapy - Methods and Clinical Development*, **2020**, 17, 209-219	6.4	10
30	Genome-Edited T Cell Therapies. *Current Stem Cell Reports*, **2017**, 3, 124-136	1.8	9
29	22q11.2 deletion syndrome with life-threatening adenovirus infection. *Journal of Pediatrics*, **2013**, 163, 908-10	3.6	9
28	Human involucrin promoter mediates repression-resistant and compartment-specific LEKTI expression. *Human Gene Therapy*, **2012**, 23, 83-90	4.8	9

27	T cell suicide gene therapy to aid haematopoietic stem cell transplantation. *Current Gene Therapy*, **2005**, 5, 121-32	4.3	9
26	Human Mesenchymal Stromal Cells Engineered to Express Collagen VII Can Restore Anchoring Fibrils in Recessive Dystrophic Epidermolysis Bullosa Skin Graft Chimeras. *Journal of Investigative Dermatology*, **2020**, 140, 121-131.e6	4.3	9
25	Multicenter phase 1/2 application of adenovirus-specific T cells in high-risk pediatric patients after allogeneic stem cell transplantation. *Cytotherapy*, **2018**, 20, 830-838	4.8	9
24	Abnormal expression of only the CD34 part of a transgenic CD34/herpes simplex virus-thymidine kinase fusion protein is associated with ganciclovir resistance. *Human Gene Therapy*, **2008**, 19, 699-709	4.8	8
23	The impact of retroviral suicide gene transduction procedures on T cells. *British Journal of Haematology*, **2003**, 123, 712-9	4.5	6
22	CRISPR-Mediated Base Conversion Allows Discriminatory Depletion of Endogenous T Cell Receptors for Enhanced Synthetic Immunity. *Molecular Therapy - Methods and Clinical Development*, **2020**, 19, 149-161	6.4	5
21	New insights into risk factors for transplant-associated thrombotic microangiopathy in pediatric HSCT. *Blood Advances*, **2020**, 4, 2418-2429	7.8	5
20	Engineered T cell therapies. *Expert Reviews in Molecular Medicine*, **2015**, 17, e19	6.7	5
19	"Darwinian" tumor-suppression model unsupported in clinical experience. *Molecular Therapy*, **2014**, 22, 1562-3	11.7	5
18	Ex vivo gene modification therapy for genetic skin diseases-recent advances in gene modification technologies and delivery. *Experimental Dermatology*, **2021**, 30, 887-896	4	5
17	Non-posttransplant lymphoproliferative disorder malignancy after hematopoietic stem cell transplantation in patients with primary immunodeficiency: UK experience. *Journal of Allergy and Clinical Immunology*, **2018**, 141, 2319-2321.e1	11.5	4
16	Administration of BPX-501 Cells Following AβT and B-Cell-Depleted HLA Haploidentical HSCT (haplo-HSCT) in Children with Acute Leukemias. *Blood*, **2018**, 132, 307-307	2.2	4
15	Reply to: "To target or not to target viral antigens in HBV related HCC?". *Journal of Hepatology*, **2015**, 62, 1450-2	13.4	3
14	Outcome of Non-hematological Autoimmunity After Hematopoietic Cell Transplantation in Children with Primary Immunodeficiency. *Journal of Clinical Immunology*, **2021**, 41, 171-184	5.7	3
13	SMiniSU6 Pol III promoter exhibits nucleosome redundancy and supports multiplexed coupling of CRISPR/Cas9 effects. *Gene Therapy*, **2020**, 27, 451-458	4	2
12	Gene Modified T Cell Therapies for Hematological Malignancies. *Hematology/Oncology Clinics of North America*, **2017**, 31, 913-926	3.1	2
11	Clinical Outcome after Adoptive Infusion of BPX-501 Cells (donor T cells transduced with iC9 suicide gene) in Children Given Alpha/Beta T-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (haplo-HSCT): Preliminary Results of a Phase I-II Trial. *Blood*, **2015**, 126, 1931-1931	2.2	2
10	Emerging therapeutic applications of CRISPR genome editing. *Emerging Topics in Life Sciences*, **2019**, 3, 257-260	3.5	1

9	TT52CAR19: Phase 1 Trial of CRISPR/Cas9 Edited Allogeneic CAR19 T Cells for Paediatric Relapsed/Refractory B-ALL. *Blood*, **2021**, 138, 4838-4838	2.2	1
8	FOXN1 forms higher-order nuclear condensates displaced by mutations causing immunodeficiency. *Science Advances*, **2021**, 7, eabj9247	14.3	1
7	Base-edited CAR T Cells for combinational therapy against T cell malignancies		1
6	Outcome of Children with Primary Immune-Deficiencies (PIDs) Enrolled in a Phase I-II Trial Based on the Infusion of BPX-501 Donor T Cells Genetically Modified with a Novel Suicide Gene (inducible Caspase 9, iC9) after T-Cell Depleted HLA-Haploidentical Allogeneic Stem Cell Transplantation (haplo-HSCT). *Blood*, **2016**, 128, 72-72	2.2	1
5	Off-the-Shelf CAR-T. *Cancer Drug Discovery and Development*, **2022**, 109-120	0.3	0
4	Off-the-Shelf Allogeneic CAR-T Cells or Other Immune Effector Cells **2022**, 51-54		
3	Administration of BPX-501 Cells Following T and B-Cell-Depleted HLA-Haploidentical HSCT (haplo-HSCT) in Children with Malignant or Non-Malignant Disorders. *Blood*, **2018**, 132, 2171-2171	2.2	
2	Rapid Expansion of Naive CD4+ Cord Blood Lymphocytes Restores Adaptive Immunity within 2 Months After Unrelated Cord Blood Transplantation. *Blood*, **2010**, 116, 2337-2337	2.2	
1	The role of immunotherapy in relapse/refractory precursor-B acute lymphoblastic leukaemia: real-life UK/Ireland experience in children and young adults. *British Journal of Haematology*, **2021**, 192, e42-e44	4.5	